These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17824016)

  • 21. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    J Nutrigenet Nutrigenomics; 2008; 1(3):126-35. PubMed ID: 19776622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
    Chan DC; Watts GF
    Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceramides in insulin resistance and lipotoxicity.
    Summers SA
    Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome.
    Shoulders CC; Naoumova RP
    Trends Mol Med; 2004 Aug; 10(8):362-5. PubMed ID: 15310455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipokines have a role to play in the treatment of metabolic disease.
    Russell ST
    Future Med Chem; 2010 Dec; 2(12):1721-4. PubMed ID: 21428794
    [No Abstract]   [Full Text] [Related]  

  • 26. [Nonalcoholic fatty liver disease and metabolic syndrome: equality of pathogenetic mechanisms and therapeutic approaches].
    Tkachenko EI; Uspenskiĭ IuP; Belousova LN; Petrenko VV
    Eksp Klin Gastroenterol; 2008; (2):92-6. PubMed ID: 19145872
    [No Abstract]   [Full Text] [Related]  

  • 27. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy.
    Oike Y; Akao M; Kubota Y; Suda T
    Trends Mol Med; 2005 Oct; 11(10):473-9. PubMed ID: 16154386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in metabolism.
    Tsoukas MA; Farr OM; Mantzoros CS
    Metabolism; 2013 Dec; 62(12):1700-13. PubMed ID: 24112391
    [No Abstract]   [Full Text] [Related]  

  • 31. [Mitochondrial dysfunction in metabolic syndrome].
    Wakino S; Itoh H
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():26-31. PubMed ID: 21766569
    [No Abstract]   [Full Text] [Related]  

  • 32. [Metabolic syndrome and Angptl family].
    Miyata K; Oike Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():319-24. PubMed ID: 21766617
    [No Abstract]   [Full Text] [Related]  

  • 33. [Endocannabinoid system and metabolic syndrome].
    Tan Z; Huang DJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):568-70. PubMed ID: 16842689
    [No Abstract]   [Full Text] [Related]  

  • 34. [EsRAGE].
    Koyama H
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():300-4. PubMed ID: 17458236
    [No Abstract]   [Full Text] [Related]  

  • 35. Bibliography. Current world literature. Lipid metabolism and therapy.
    Curr Opin Clin Nutr Metab Care; 2011 Mar; 14(2):213-6. PubMed ID: 21311253
    [No Abstract]   [Full Text] [Related]  

  • 36. [Molecular mechanisms of lipid metabolism in metabolic syndrome].
    Hirata K
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():79-83. PubMed ID: 17824016
    [No Abstract]   [Full Text] [Related]  

  • 37. An update on lipidomics: progress and application in biomarker and drug development.
    Han X
    Curr Opin Mol Ther; 2007 Dec; 9(6):586-91. PubMed ID: 18041669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans.
    Lafontan M; Moro C; Sengenes C; Galitzky J; Crampes F; Berlan M
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2032-42. PubMed ID: 16123323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.